Executive Overview: The Evolving Paradigm of Treatment-Resistant Psoriasis

Psoriasis vulgaris is a chronic, immune-mediated inflammatory dermatosis historically viewed as an isolated disorder of epidermal hyperkeratosis. Modern molecular pathology recognizes it as a systemic condition sustained by an aberrant interleukin-23 (IL-23) / T-helper 17 (Th17) / interleukin-17 (IL-17) cytokine axis.

A significant cohort of patients develop treatment-resistant disease, characterized by:

• Primary failure: Inability to achieve a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) or PASI 50 with a Dermatology Life Quality Index (DLQI) improvement of at least 5 points after an induction course of first-line systemic therapies.
• Secondary failure: Progressive loss of efficacy over time due to anti-drug antibody formation, immunogenicity, or phenotypic shifts.
• Recalcitrant anatomical sites: Persistent disease localized to high-impact areas such as the scalp, palms, soles, intertriginous folds, and nail units.
• Inflammatory articular involvement: Concurrent psoriatic arthritis leading to irreversible joint destruction.

For decades, oral small molecules—methotrexate, cyclosporine, and acitretin—formed the therapeutic standard. While accessible and familiar, they carry shallow efficacy plateaus and cumulative end-organ risks.

Targeted biologics have redefined therapeutic goals: shifting expectations from disease reduction toward complete or near-complete clearance (PASI 90, PASI 100, and absolute PASI of 2 or less). Within this framework, selective IL-17 and IL-23 inhibitors offer durable disease control, outperforming legacy therapies and early biological classes.

1. Pathophysiological Foundations: The Molecular Axis of Recalcitrant Psoriasis

The chronic inflammatory feedback loop in psoriasis involves coordination between innate triggers, dendritic cells, specialized T-cell subsets, and structural keratinocytes.

Physical micro-trauma, environmental stress, or systemic infections prompt stressed keratinocytes to release antimicrobial peptides, primarily the cathelicidin peptide LL-37, complexed with self-nucleic acid fragments. These complexes bind Toll-Like Receptors 7 and 9 (TLR7/9) within plasmacytoid dendritic cells, stimulating the release of Type I Interferons (IFN-alpha and IFN-beta). This interferon cascade activates dermal myeloid dendritic cells to produce high concentrations of Interleukin-23.

Interleukin-23 is a heterodimeric cytokine consisting of a unique p19 subunit linked to a shared p40 subunit. IL-23 binds the IL-23R/IL-12R-beta-1 complex on naive and memory T-cells. This engagement activates the Janus Kinase 2 (JAK2) and Tyrosine Kinase 2 (TYK2) pathways, driving phosphorylation of Signal Transducer and Activator of Transcription 3 (STAT3). Nuclear translocation of STAT3 upregulates the transcription factor ROR-gamma-t, driving the differentiation, proliferation, and survival of pathogenic Th17 and Tc17 populations.

Dermal Th17, Tc17, and innate lymphoid cells secrete the downstream effector cytokines IL-17A, IL-17F, and the IL-17A/F heterodimer. These ligands engage the IL-17RA/IL-17RC receptor complex on epidermal keratinocytes. Receptor docking recruits the Act1 adapter protein, activating the NF-kappa-B and MAP kinase cascades.

Keratinocytes respond by producing:

• Neutrophil-attracting chemokines (CXCL1, CXCL8), forming microabscesses within the stratum corneum.
• Pro-angiogenic factors (VEGF), producing tortuous capillary loops in the dermal papillae.
• Antimicrobial peptides (S100A7, beta-defensins), which re-stimulate dendritic cells and lock the tissue in continuous inflammation.

2. Targeted Biologics: Interleukin-17 and Interleukin-23 Inhibitors

Targeted biological therapeutics fall into two primary upstream/downstream classes.

• Secukinumab: A fully human IgG1-kappa monoclonal antibody that neutralizes soluble IL-17A homodimers. Dosed at 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. In clinical trials, PASI 90 is achieved in 54% to 60% of patients by Week 12, with rapid reduction in pruritus.
• Ixekizumab: A humanized IgG4 monoclonal antibody with high binding affinity for IL-17A and IL-17A/F. Dosed with a 160 mg loading dose, followed by 80 mg every 2 weeks through Week 12, then 80 mg every 4 weeks. It yields PASI 90 rates of 68% to 71% and PASI 100 in up to 40% of patients at Week 12.
• Bimekizumab: A humanized IgG1 antibody that neutralizes both IL-17A and IL-17F. Concurrently blocking IL-17F suppresses downstream keratinocyte activation more completely than selective IL-17A blockade alone. Dosed at 320 mg every 4 weeks through Week 16, then every 8 weeks. In head-to-head trials, it achieved PASI 100 in over 60% of patients by Week 16.
• Brodalumab: A fully human IgG2 antibody directed against the IL-17RA receptor subunit, blocking signaling from IL-17A, IL-17F, and IL-25. Dosed at 210 mg subcutaneously at Weeks 0, 1, and 2, then every 2 weeks. It delivers rapid clearance, achieving PASI 100 in 44% of patients by Week 12.

• Guselkumab: A fully human IgG1-lambda antibody targeting the p19 subunit of IL-23. Dosed at 100 mg subcutaneously at Weeks 0, 4, and every 8 weeks thereafter. It achieves PASI 90 in roughly 73% of patients at Week 16, maintaining high clearance through five years of therapy.
• Risankizumab: A humanized IgG1 antibody targeting the p19 subunit. Dosed at 150 mg subcutaneously at Weeks 0, 4, and every 12 weeks. Clinical trials show PASI 90 rates of 75% at Week 16, rising above 85% at Week 52, with roughly half of all patients maintaining complete PASI 100 clearance.
• Tildrakizumab: A humanized IgG1-kappa antibody targeting the p19 subunit. Dosed at 100 mg (or 200 mg for patients over 90 kg) at Weeks 0, 4, and every 12 weeks. It provides consistent disease suppression with minimal risk of injection-site or systemic reactions.

3. Traditional Systemic Agents: Mechanics and Limitations

Methotrexate is a competitive antagonist of dihydrofolate reductase that inhibits DNA synthesis in rapidly dividing cells. In chronic inflammatory skin disease, its primary anti-inflammatory mechanism occurs through AICAR transformylase inhibition, elevating extracellular adenosine levels, which downstream suppresses IL-23 and TNF production.

• Dosing: 10 to 25 mg administered once weekly, accompanied by 1 to 5 mg of daily folic acid (omitted on the day of methotrexate).
• Limitations: Monotherapy PASI 75 rates hover between 35% and 40% at Week 16. Long-term use is constrained by cumulative hepatotoxicity, hepatic fibrosis, myelosuppression, and teratogenicity.

Cyclosporine binds intracellular cyclophilin to inhibit calcineurin, preventing the dephosphorylation of nuclear factor of activated T-cells (NFAT) and halting IL-2 transcription.

• Dosing: 2.5 to 5.0 mg/kg/day divided into two daily doses.
• Limitations: While it acts rapidly, international guidelines restrict continuous treatment to 1 to 2 years due to risks of structural renal vasoconstriction, irreversible interstitial nephritis, secondary arterial hypertension, and increased rates of cutaneous squamous cell carcinoma.

A synthetic oral retinoid that binds nuclear retinoic acid receptors (RARs) to normalize epidermal differentiation without direct immunosuppression.

• Dosing: 10 to 35 mg daily with a fat-rich meal.
• Limitations: Modest clearance rates in classic plaque disease (PASI 75 in 20% to 30%). It requires absolute pregnancy prevention during therapy and for 3 years post-cessation due to metabolic conversion to etretinate, which is stored in body fat.

4. Head-to-Head Comparative Overview

• Target Specificity: Interleukin inhibitors selectively block isolated cytokine ligands or explicit receptor chains, preserving general immune surveillance. Traditional agents exert broad anti-proliferative, immunosuppressive, or transcriptional effects across multiple organ systems.
• Clearance Depth: IL-17 and IL-23 inhibitors routinely achieve PASI 90 in 70% to 85% of patients and PASI 100 in 40% to 60%. Traditional systemics reach a functional ceiling at PASI 75 (achieved in 30% to 50% of patients), rarely sustaining complete clearance.
• Response Velocity: IL-17 inhibitors and cyclosporine produce rapid clinical responses within 2 to 4 weeks. IL-23 inhibitors reach peak clearance between Weeks 16 and 24, while methotrexate and acitretin require 12 to 16 weeks to demonstrate efficacy.
• Safety and Monitoring: Biologics require initial infectious screening for latent tuberculosis and viral hepatitis, with minimal maintenance laboratory monitoring. Traditional agents demand continuous serial blood counts, metabolic panels, and renal or hepatic tracking every 4 to 12 weeks.
• Organ Toxicity: Interleukin inhibitors do not cause cumulative liver or kidney toxicity. Traditional agents carry risks of hepatic fibrosis (methotrexate), chronic kidney disease (cyclosporine), and severe hyperlipidemia or teratogenicity (acitretin).

5. Adverse Effect Profiles and Clinical Decision Scenarios

• IL-17 Inhibitors: Require surveillance for superficial mucocutaneous candidiasis (managed with oral fluconazole without interrupting biologic therapy) and are contraindicated in patients with inflammatory bowel disease due to the protective role of IL-17 in gut epithelial integrity. Brodalumab carries a warning regarding monitoring for mood changes and depressive symptoms.
• IL-23 Inhibitors: Favorable safety profiles with low rates of opportunistic infections, no signal for inflammatory bowel disease flares, and low immunogenicity.
• Traditional Agents: Carry risks of marrow suppression, chemical hepatitis, arterial hypertension, and embryofetal lethality.

• Psoriasis with Inflammatory Bowel Disease: Initiate a p19-selective IL-23 inhibitor (such as risankizumab or guselkumab), which addresses both cutaneous and intestinal inflammation while avoiding the mucosal barrier disruption linked to IL-17 inhibition.
• Psoriasis with Axial Spondyloarthritis: Select an IL-17 inhibitor (ixekizumab, secukinumab, or bimekizumab), as this class demonstrates proven efficacy in controlling spinal inflammation and preventing radiographic progression, where IL-23 inhibitors have failed to show benefit.
• Acute Erythrodermic or Pustular Crisis: Use a short-term cyclosporine bridge (3.5 to 5.0 mg/kg/day) to regain barrier integrity within 72 hours, paired with the initiation of an IL-23 or IL-17 biologic to take over as cyclosporine is tapered over 4 weeks.
• Patients with High Infection Risks or Latent Tuberculosis: Select an IL-23 inhibitor alongside appropriate anti-tubercular chemoprophylaxis, taking advantage of the preserved IL-12/Th1 pathway for host defense.

6. Phased Transition Protocol

Transitioning a patient from a failing traditional systemic drug to an interleukin inhibitor requires structured steps to prevent disease rebound:

1. Document Treatment Failure: Confirm the patient completed an adequate therapeutic course (at least 12 weeks at therapeutic doses) and rule out non-adherence or drug interactions.
2. Pre-Biologic Screening: Obtain baseline IGRA tuberculosis testing, complete hepatitis B and C serologies, and ensure required non-live vaccinations are complete.
3. Execute Overlapping Induction: When stopping methotrexate, initiate the biologic at Week 0 while maintaining reduced-dose methotrexate (7.5 to 10 mg/week) for 2 to 4 weeks before full withdrawal. If tapering cyclosporine, step down the daily dose by 25% every 7 to 10 days during biologic induction to prevent acute rebound.
4. Monitor Early Adverse Indicators: Inspect oral and genital mucosa for candidiasis if initiating an IL-17 inhibitor, and screen for unexpected changes in bowel habits.
5. Evaluate Primary Endpoints: Measure objective clearance at Week 12 for IL-17 inhibitors and Week 16 for IL-23 inhibitors, targeting PASI 90 or an absolute PASI score of 2 or less.
6. Establish Long-Term Surveillance: Maintain regular 6-month clinical reviews to assess treatment durability, track joint symptoms, and confirm ongoing therapeutic efficacy.

10 Frequently Asked Questions (FAQs)

It is defined as the failure to achieve at least a PASI 75 response (or PASI 50 with a DLQI improvement of at least 5 points) after a standard 12- to 16-week course of an optimized systemic agent, the loss of an established response over time, or recalcitrant disease in high-impact sites like the scalp, palms, soles, and nails.

Interleukin inhibitors selectively target the core driving cytokines of psoriasis rather than suppressing broad cellular replication. This delivers higher skin clearance rates (PASI 90/100) with minimal end-organ toxicity and eliminates the need for frequent laboratory monitoring.

Secukinumab and Ixekizumab selectively neutralize IL-17A. Bimekizumab dual-inhibits both IL-17A and IL-17F, shutting down additional inflammatory signaling through the IL-17RA/RC complex and producing higher rates of complete clearance (PASI 100).

IL-17A supports the mucosal barrier in the gut by maintaining tight-junction proteins. Blocking IL-17 can disrupt intestinal integrity, triggering new-onset inflammatory bowel disease or worsening quiescent disease.

A p19-selective IL-23 inhibitor (such as risankizumab) is preferred because it treats cutaneous and intestinal inflammation without compromising the mucosal barrier.

No. While IL-23 inhibitors are effective for peripheral joint disease and enthesitis, randomized clinical trials demonstrate they do not control axial spondyloarthritis. An IL-17 inhibitor is preferred when spinal involvement is present.

Biologics require several weeks to reach steady-state therapeutic levels. Abruptly stopping methotrexate or cyclosporine leaves an immunosuppressive gap that can trigger rebound disease flares.

Guidelines recommend limiting continuous cyclosporine use to 1 to 2 years to minimize the risk of irreversible renal arteriolar damage, interstitial fibrosis, and secondary skin malignancies.

In the presence of trace amounts of alcohol, acitretin converts into etretinate, a teratogenic compound that stores in body fat and has an elimination half-life of 120 to 160 days.

Patients should receive an Interferon-Gamma Release Assay (QuantiFERON-TB Gold) or T-SPOT test, a baseline chest radiograph, and serological screening for Hepatitis B and Hepatitis C.